Patients taking ropinirole may require dosing adjustments with the introduction, withdrawal or dose adjustment in any of these medications.
Some patients in the 15-min cohort had the option of receiving 2- to 5-min infusions on day 8. Intravenously administered drugs are essentially 100% bioavailable; therefore, switching to an intravenous formulation from a <100% bioavailable oral formulation, such as carbamazepine, may require dosing adjustments to maintain therapeutic plasma drug concentrations.
Comparisons concerning the numbers of drugs that may require dose adjustments were done using the two-sided Friedman- or Wilcoxon-test, as appropriate.
As tolvaptan is also primarily metabolized by the CYP3A4 pathway, coadministration of calcium channel blockers, macrolide antibiotics, or azole antifungals may require dose adjustments.
As concomitant administration of NEPA may increase the plasma concentration for drugs that are mainly metabolized via CYP3A4, coadministration with other drugs that are substrates of CYP3A4 may require dose adjustments.
Netupitant is a substrate and moderate inhibitor of the cytochrome P450 isoenzyme 3A4 (CYP3and and therefore, as is the case with another NK1 RA, aprepitant, coadministration with drugs that are substrates of CYP3A4 may require dose adjustments [ 29– 31].
Pre-existing hepatic disease may alter the metabolic clearance of some antidepressants and may necessitate dose adjustment [ 134].
Thus, initiation of GH therapy in patients with subclinical adrenocorticotropic hormone deficiency may induce symptomatic adrenal insufficiency requiring glucocorticoid substitution, and patients already on cortisol replacement may need dose adjustment.
Therefore, modulation of CYP3A enzyme activity in smokers may require dose adjustment for some inhaled drugs.
These changes could result in suboptimal treatment, particularly for time-dependent antibiotics, and may necessitate dose adjustment.
